Tag Archives: Janus Henderson Investors

← Older posts

Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward

Had things turned out differently, scientists at Galecto might be watching their idiopathic pulmonary fibrosis drug candidate develop in the hands of a big pharmaceutical company. But Bristol Myers Squibb passed on its option to acquire Galecto leaving the biotech to forge ahead on its own. Now the company has $64 million to advance clinical […]

Posted in Boston blog main, Boston top stories, Europe, Europe blog main, Europe top stories, National blog main, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward

Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies

Drugs designed to precisely target cancers with specific genetic signatures have changed the course of disease for many patients. But for the majority, such drugs either don’t work because of innate resistance or they eventually stop working once the cancer develops new mutations that hamper their effectiveness. Kinnate Biopharma, one of the biotechs working to […]

Posted in National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies

Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early

The ability to detect early signs of cancer in a patient’s blood could improve prognoses by helping doctors treat the disease before symptoms arise. Freenome, one of the companies racing to commercialize the first such screening test, on Wednesday announced it raised $270 million—money it plans to accelerate a clinical study of an experimental screening […]

Posted in Boston blog main, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early

Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study. Many cancers grow silently, and once malignant cells are discovered a patient’s prognosis […]

Posted in Boston blog main, Boston top stories, National, National blog main, National top stories, San Diego blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test

Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate

Olema Oncology has raised $54 million to advance its lead drug candidate into human tests, having been working in stealth since 2007 to develop a daily pill to treat women with breast cancer whose disease is driven by the hormone estrogen. San Francisco-based Olema announced Wednesday that the Series B financing round will allow it to start […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , | Comments Off on Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company’s goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration

Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing its preclinical pipeline. The South San Francisco-based company is developing drugs for patients with autoimmune and neurodegenerative disorders that are caused by an abnormal […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration

Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better

Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. This cancer immunotherapy approach has saved countless lives and turned drugs from Merck and Bristol Myers Squibb into blockbuster products. But what if a single drug could block checkpoint proteins while simultaneously sparking an anti-tumor response? That’s […]

Posted in Boston blog main, Boston top stories, Europe blog main, Europe top stories, National blog main, New York blog main, New York top stories, Raleigh-Durham, Raleigh-Durham blog main, Raleigh-Durham top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better

C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

C4 Therapeutics, a biotech developing small molecules designed to take advantage of a cellular mechanism as a way to treat disease, has raised $170 million in venture equity and debt to start human testing. The Watertown, MA-based firm is among a number of companies competing in the popular protein degradation space, in which drug developers […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic

Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised $102 million to move into clinical testing next year. The Series C round of […]

Posted in Boston, Boston blog main, Boston top stories, Europe blog main, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic← Older posts